STAT44%
FDA approves Vera Therapeutics kidney disease treatment 9%
By Adam Feuerstein43%
7/7/2026, 4:44:36 PM
BS Summary: This article contains 4 faulty reasoning types, including Self-Serving Bias, Appeal to Emotion, and Attempt to Sell a Product or Service, with Optimism Bias as the most egregious example at 24% saturation with 23 hits. Analysis detected 92 faulty-reasoning hits from 96 analyzed words, generating a BS Score of 25.8% and a BS Rank of 9% (19,971 of 21,886 articles). This article is better (less manipulative) than 91.20% of the article peer group.
The Food and Drug Administration on Tuesday approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
The drug, called Trutakna, was cleared to treat IgA nephropathy, or IgAN, a disease caused by the buildup of immune antibodies in the kidneys.
The condition leads to progressive loss of kidney function and potentially organ failure requiring dialysis.
“We’re extremely excited to bring Trutakna to patients,” Vera CEO Marshall Fordyce told STAT, in an interview conducted ahead of the FDA approval.
Speakers
1speaker24%attributed speech73writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageMarshall Fordyce
23 attributed words100% of attributed speech0% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.